ATE490975T1 - 4-methylhexanoic kahalalide f verbindung - Google Patents

4-methylhexanoic kahalalide f verbindung

Info

Publication number
ATE490975T1
ATE490975T1 AT03779140T AT03779140T ATE490975T1 AT E490975 T1 ATE490975 T1 AT E490975T1 AT 03779140 T AT03779140 T AT 03779140T AT 03779140 T AT03779140 T AT 03779140T AT E490975 T1 ATE490975 T1 AT E490975T1
Authority
AT
Austria
Prior art keywords
kahalalide
methylhexanoic
compound
antitumoral
antiviral
Prior art date
Application number
AT03779140T
Other languages
German (de)
English (en)
Inventor
Glynn Faircloth
Mariano Elices
Halina Sasak
Marin Pablo Aviles
Marchante Maria Del Carmen Cuevas
Original Assignee
Pharma Mar Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2002/004735 external-priority patent/WO2003033012A1/en
Priority claimed from GBGB0304367.6A external-priority patent/GB0304367D0/en
Priority claimed from GB0314725A external-priority patent/GB0314725D0/en
Application filed by Pharma Mar Sau filed Critical Pharma Mar Sau
Priority claimed from PCT/US2003/033207 external-priority patent/WO2004035613A2/en
Application granted granted Critical
Publication of ATE490975T1 publication Critical patent/ATE490975T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03779140T 2002-10-18 2003-10-20 4-methylhexanoic kahalalide f verbindung ATE490975T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2002/004735 WO2003033012A1 (en) 2001-10-19 2002-10-18 Kahalalide compounds for use in cancer therapy
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
GB0314725A GB0314725D0 (en) 2003-06-24 2003-06-24 New antitumoral compounds
PCT/US2003/033207 WO2004035613A2 (en) 2002-10-18 2003-10-20 4-methylhexanoic kahalaide f compound

Publications (1)

Publication Number Publication Date
ATE490975T1 true ATE490975T1 (de) 2010-12-15

Family

ID=35276268

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03779140T ATE490975T1 (de) 2002-10-18 2003-10-20 4-methylhexanoic kahalalide f verbindung

Country Status (11)

Country Link
KR (2) KR20110114690A (pl)
AT (1) ATE490975T1 (pl)
AU (1) AU2003285911B2 (pl)
CY (1) CY1111319T1 (pl)
DE (1) DE60335292D1 (pl)
DK (1) DK1572726T3 (pl)
IL (1) IL167724A (pl)
NO (1) NO333448B1 (pl)
PL (1) PL209129B1 (pl)
PT (1) PT1572726E (pl)
SI (1) SI1572726T1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
MXPA03003704A (es) * 2000-10-31 2004-05-04 Pharma Mar Sa Formulacion de kahalalide f.
EP1435990A1 (en) * 2001-10-19 2004-07-14 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
KR20110114690A (ko) 2011-10-19
DK1572726T3 (da) 2011-03-28
PL377056A1 (pl) 2006-01-23
CY1111319T1 (el) 2015-08-05
AU2003285911A1 (en) 2004-05-04
NO333448B1 (no) 2013-06-10
HK1082261A1 (en) 2006-06-02
NO20052379D0 (no) 2005-05-13
PT1572726E (pt) 2011-02-14
KR20050070056A (ko) 2005-07-05
SI1572726T1 (sl) 2011-04-29
KR101149095B1 (ko) 2012-05-30
DE60335292D1 (de) 2011-01-20
IL167724A (en) 2012-01-31
AU2003285911B2 (en) 2009-11-19
PL209129B1 (pl) 2011-07-29
NO20052379L (no) 2005-07-15

Similar Documents

Publication Publication Date Title
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
DK1663242T3 (da) 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
EA200400971A1 (ru) Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения
EA200500392A1 (ru) Производные пиримидина и их применение в качестве модуляторов св2
BR0211390A (pt) Tratamento de infecções da unha com no
EA200500856A1 (ru) Новые химические соединения
ITMI20052171A1 (it) Composti e-amminocarbonil bicicloepten pirimidindiamminici stereoisomericamente arricchiti e loro uso
BG66080B1 (bg) Заместени тиоацетамиди
MXPA04003796A (es) Tioacetamidas sustituidas.
NO20082298L (no) Kaliumkanalinhibitorer
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
ATE486915T1 (de) Azeotrop-ähnliche zusammensetzung von 1,2-dichlor-3,3,3-trifluorpropen und fluorwasserstoff
MXPA05004133A (es) Nuevos compuestos antitumorales.
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
SE9901077D0 (sv) Novel use
DE602004028493D1 (de) Isochinolinon-kaliumkanalinhibitoren
BR0115139A (pt) Compostos bis-heterocìclicos com atividade antitumor e quimiossensibilizante
ATE372330T1 (de) N-sulfonylurea-apoptosis-förderer
DE60213802D1 (de) Cak inhibitoren und deren verwendungen
CY1111319T1 (el) Ενωση 4-μεθυλεξανοϊκης κααλαλιδης f
BR0312183A (pt) Uso de compostos benzisosselenazolonas contra lesão miocárdica isquêmica
ES2194744T3 (es) Derivados de quinocardina, su procedimiento de preparacion y su aplicacion como antifungicos.
ATE286890T1 (de) Biologisch wirksame, analoge verbindungen von discodermoliden
EA200501259A1 (ru) Комбинированное применение фибрата и орлистата для лечения ожирения
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1572726

Country of ref document: EP